To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of INNO-406 when administered as a single agent to adult patients with imatinib-resistant or intolerant Ph+ leukemias. One year [clinicaltrials_resource:53de3a681a0ded64457a311c4f638bc0]
Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of INNO-406 when administered as a single agent to adult patients with imatinib-resistant or intolerant Ph+ leukemias. One year [clinicaltrials_resource:53de3a681a0ded64457a311c4f638bc0]
Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
Bio2RDF identifier
53de3a681a0ded64457a311c4f638bc0
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:53de3a681a0ded64457a311c4f638bc0
measure [clinicaltrials_vocabulary:measure]
To determine the maximum toler ...... t or intolerant Ph+ leukemias.
time frame [clinicaltrials_vocabulary:time-frame]
description
Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
identifier
clinicaltrials_resource:53de3a681a0ded64457a311c4f638bc0
title
To determine the maximum toler ...... lerant Ph+ leukemias. One year
@en
type
label
To determine the maximum toler ...... e3a681a0ded64457a311c4f638bc0]
@en